We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

89 hedge funds and large institutions have $113M invested in Gyre Therapeutics in 2021 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 39 increasing their positions, 18 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

406% more call options, than puts

Call options by funds: $2.92M | Put options by funds: $577K

117% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 18

100% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 9

25% more capital invested

Capital invested by funds: $90.2M → $113M (+$22.7M)

11% more funds holding

Funds holding: 80 → 89 (+9)

0.91% more ownership

Funds ownership: 8.63% → 9.54% (+0.91%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
89
Holders Change
+9
Holders Change %
+11.25%
% of All Funds
1.56%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
18
Increased
39
Reduced
18
Closed
9
Calls
$2.92M
Puts
$577K
Net Calls
+$2.35M
Net Calls Change
+$2.02M

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$12.9M
2
SCM
Stonepine Capital Management
Oregon
+$9.85M
3
OM
Opaleye Management
Massachusetts
+$6.71M
4
GTC
Ghost Tree Capital
New York
+$6.09M
5
NCM
Nantahala Capital Management
Connecticut
+$4.24M

Top Sellers

Rank Fund Capital Flow
1
ACM
AIGH Capital Management
Maryland
-$2.66M
2
ACP
Acuta Capital Partners
California
-$2.55M
3
ACM
Altium Capital Management
New York
-$1.36M
4
Renaissance Technologies
Renaissance Technologies
New York
-$918K
5
Millennium Management
Millennium Management
New York
-$882K
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$640K +$263K +5,757 +52%
N
27
Nuveen
North Carolina
$559K +$187K +4,091 +38%
RJFSA
28
Raymond James Financial Services Advisors
Florida
$512K +$133K +2,906 +27%
MHS
29
M Holdings Securities
Oregon
$475K -$204K -4,467 -26%
ACM
30
Altium Capital Management
New York
$453K -$1.36M -29,842 -71%
SSA
31
Schonfeld Strategic Advisors
New York
$431K +$520K +11,387 New
Charles Schwab
32
Charles Schwab
California
$397K +$168K +3,667 +54%
EWM
33
Essex Woodlands Management
Texas
$396K – – –
Squarepoint
34
Squarepoint
New York
$352K +$425K +9,306 New
BFM
35
Boothbay Fund Management
New York
$345K +$417K +9,123 New
JJIJ
36
Johnson & Johnson Innovation - JJDC
New Jersey
$337K – – –
DC
37
Davenport & Co
Virginia
$316K +$21.3K +467 +6%
Bank of America
38
Bank of America
North Carolina
$306K +$204K +4,470 +124%
Morgan Stanley
39
Morgan Stanley
New York
$302K +$252K +5,506 +223%
AA
40
AlphaCentric Advisors
Puerto Rico
$302K +$366K +8,000 New
Wells Fargo
41
Wells Fargo
California
$283K -$59.4K -1,300 -15%
Barclays
42
Barclays
United Kingdom
$282K +$163K +3,569 +92%
PP
43
PDT Partners
New York
$277K +$123K +2,693 +58%
Russell Investments Group
44
Russell Investments Group
United Kingdom
$269K -$19.1K -418 -6%
Ameriprise
45
Ameriprise
Minnesota
$244K -$3.66K -80 -1%
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$234K +$79.3K +1,736 +39%
PPA
47
Parametric Portfolio Associates
Washington
$220K -$868 -19 -0.3%
TAM
48
Tocqueville Asset Management
New York
$199K -$67.1K -1,467 -22%
BDF
49
Black Diamond Financial
Maryland
$192K +$232K +5,067 New
Susquehanna International Group
50
Susquehanna International Group
Pennsylvania
$177K +$139K +3,048 +188%
1
2
3 4

GYRE Hedge Fund Activity: Q1 2021 in Review

89 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2021, worth a combined $113M — up 25% from $90.2M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new GYRE positions and 9 closed out — a net gain of 9 holders — while 39 added to existing stakes and 18 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $12.9M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $2.66M sold.

  • 89 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2021, up from 80 in Q4 2020.
  • Funds reported $113M of Gyre Therapeutics stock for Q1 2021, up 25% quarter-over-quarter.
  • 18 funds opened new Gyre Therapeutics positions in Q1 2021 and 9 closed out, a net change of +9 holders.
  • The largest Gyre Therapeutics buyer in Q1 2021 was OrbiMed, an estimated $12.9M added.
  • The largest Gyre Therapeutics seller in Q1 2021 was AIGH Capital Management, an estimated $2.66M sold.

Based on aggregated 13F filings for Q1 2021.